Neoplasms

All Conditions

Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Antineoplastic Agents

All Drugs and Chemicals

Cisplatin

Endostar protein

Endostatins

Angiogenesis Inhibitors

Growth Inhibitors

4 cycles of Endostar and 5 cycles of DDP concurrent with radiotherapy

5 cycles of DDP concurrent with radiotherapy

Endostar: 7.5mg/m2 d1-10, repeat every 15 days, for 4 cycles

Endostar

Yong Zhang, MD

Fang Wu, MD

Yong Zhang, M.D.

Fang Wu, M.D.

Jian Li, M.D.

Hemin Lu, M.D.

Haixin Huang, Master

Zhanxiong Luo, Master

Meilian Liu, Master

Gaojuan Lin, Master

Sihui Liao, bachelor

Hongqian Wang, bachelor

A total of 120 patients with pathologically confirmed Locally advanced cervical carcinoma were enrolled. Patients were randomly divided into two groups, with 60 patients in each group. One group was treated with Concurrent Chemoradiotherapy combined with Endostar and the other group was treated with Concurrent Chemoradiotherapy. The short term efficacy and the toxic of these treatments were evaluated. The 1-year, 3-year, 5-year overall survival and progression-free survival of patients were analyzed. The investigators data may provide an alternative option for the treatment of Locally advanced cervical carcinoma with high efficacy and low toxicity.

This study was a multicenter, randomized controlled clinical trial. A set of unified standards were used, including the clinical research program, inclusion criteria, exclusion criteria, chemoradiotherapy regimen and evaluation criteria. Nine medical centers participated in this study and 120 patients with pathologically confirmed Locally advanced cervical carcinoma were enrolled. These patients were randomly divided into two groups: concurrent chemoradiotherapy combined with Endostar group ( IMRT 45-50Gy, DDP 40mg/m2, per week for 5cycles, Endostar: 7.5mg/m2 d1-10, repeat every 15 days, for 4 cycles) and concurrent chemoradiotherapy group ( IMRT 45-50Gy, DDP 40mg/m2, per week, for 5cycles). After treatment, follow-up was performed every 3 months. The treatment toxicity, local control rate, distant metastasis-free survival, overall survival, progression-free survival were observed and assessed.

Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma

A Multicenter, Randomized Controlled Clinical Trial Comparing Endostar With Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Carcinoma

3 months after treatment, the subjects go into observation period. MRI/CT will be used for evaluating the carcinoma status.

OS was calculated from the date of entry into the study to the date of death or the last follow-up visit.

PFS was calculated from the date of entry into the study to the date of first physical or radio-graphic evidence of disease progression, death or the last follow-up visit.

Yong Zhang,MD

Ear, Nose, and Throat Diseases

Symptoms and General Pathology

Substance Related Disorders

Wounds and Injuries

Head and Neck Neoplasms

Ototoxicity

Ear Diseases

Otorhinolaryngologic Diseases

Drug-Related Side Effects and Adverse Reactions

Chemically-Induced Disorders

Radiation Injuries

Micronutrients

Pharmaceutical Solutions

Anti-Infective Agents

Vitamins

Vitamin A

Retinol palmitate

Hyaluronic Acid

Sodium thiosulfate

Antidotes

Protective Agents

Antioxidants

Antitubercular Agents

Anti-Bacterial Agents

Chelating Agents

Retinol

Trans-tympanic injection of a sodium thiosulfate gel

A sodium thiosulfate hyaluronate gel will be prepared by mixing 0.55 ml of a 25% solution of sodium thiosulfate pentahydrate (Seacalphyx, DIN 02386666, Seaford Pharmaceuticals Inc.) and 0.55 ml of a hyaluronate gel (Healon 10 mg, Abbott Medical Optics Inc.). On the day before each Cisplatin treatment an otologist will deposit 0.1 ml of the gel exactly on the round window of the middle ear.

Francois Meyer, MD, DSc

This study evaluates whether a gel containing sodium thiosulfate deposited via a trans-tympanic injection on the round window of the middle ear could reduce the ototoxicity caused by the drug Cisplatin among patients with head and neck cancer treated by chemoradiation. One ear selected randomly will be treated while the other will serve as control.

Background

Cisplatin (cis-DiammineDichloridoPlatinum, DDP) is an antineoplastic agent used in the treatment of solid malignant tumors in adults and is also a key part of treatment for many children and adolescents with cancer. However, treatment with Cisplatin carries the risk of serious dose-limiting adverse effects. Ototoxicity is of major concern since the associated hearing loss greatly impairs patients' quality of life and no preventive treatment is presently available. Cisplatin ototoxicity is an important problem for patients treated for head and neck squamous cell carcinoma (HNSCC) who receive repeatedly high doses.

Cisplatin causes an accumulation of reactive oxygen species (ROS) in the cochlea, triggering damage to the outer hair cells of the organ of Corti. Sulfur-containing antioxidants can neutralize ROS following Cisplatin intoxication, and thus represent a potential preventive measure. A few sulfur-containing molecules have been studied. Experimental and human studies have shown that sodium thiosulfate (STS) can protect against Cisplatin-induced ototoxicity. However, when administered through the blood stream, STS interfere with Cisplatin treatment efficacy. To counter the ototoxic effects of Cisplatin treatment without impairing its efficacy, a local pharmacology approach directly aiming at the cochlea, would represent a powerful clinical strategy.

The proposed study is the first to test the efficacy of STS administered locally in the middle ear to prevent Cisplatin-induced ototoxicity in humans.

Objective

The objective of this study is to test the efficacy of trans-tympanic injections of a sodium thiosulfate-hyaluronate gel prior to cisplatin treatments to prevent cisplatin-induced ototoxicity in patients with locally advanced head and neck cancer.

The principal objective is to test the efficacy of the trans-tympanic injections of the gel at pure tone high frequencies. Exploratory analyses for secondary objectives will assess 1) cochlear damage, specifically hair cell function and 2) hearing loss at frequencies used for speech perception. Other outcomes considered are the severity of ototoxicity and the adverse effects of the trans-tympanic injections.

Methods

The proposed study is a randomized controlled trial. For each participant, one randomly selected ear will receive the treatment while the other ear will not. For ethical reasons, the control ear will not receive a placebo injection.

Participants to the trial will be recruited at the radiation therapy department of the CHU de Québec. Eligible participants are patients newly diagnosed with a locally advanced squamous cell carcinoma of the head and neck scheduled to be treated with concomitant chemoradiation. This treatment includes Cisplatin 100 mg/m2 on days 1, 22, and 43 after the first radiation fraction.

At the end of the first day of radiation therapy, the pharmacy department of the CHU de Québec will prepare the sodium thiosulfate hyaluronate gel by mixing 0.55 ml of a 25% solution of sodium thiosulfate pentahydrate (Seacalphyx, Drug identification number (DIN) 02386666, Seaford Pharmaceuticals Inc.) and 0.55 ml of a hyaluronate gel (Healon 10 mg, Abbott Medical Optics Inc.). After a local anesthesia of the tympanic membrane, the otologist will deposit 0.1 ml of the gel exactly on the round window of the middle ear. From there the STS should diffuse towards the cochlea. The same procedure will be repeated on the eve of the subsequent Cisplatin treatments on days 22 and 43.

To assess the effect of the trial intervention, a complete audiologic evaluation will be conducted before and one month after the end of chemoradiation therapy. The CHU de Québec audiologists will perform audiograms at frequencies ranging from 0.5 to 14 kHz. Sound intensity will be measured as dBHL(decibel hearing level). Speech reception thresholds will also be assessed. In addition, distortion product otoacoustic emissions (DPOAEs) recording will also be performed. Otoacoustic emissions measurements could detect hair cell damage due to Cisplatin early. The final audiologic evaluation will be conducted by an audiologist blinded to the ear assignment who would not have access to the trial and hospital records.

Adverse effects of the transtympanic injection will be documented according to the Common Terminology Criteria for Adverse Events v4.0 (CTCAE). In addition, to identify unexpected adverse effects of the trial intervention on hearing, a shorter unblinded audiogram will be conducted before proceeding to the second and third transtympanic injections. Data from these audiograms will not be used in the main analysis.The follow-up for audiologic safety monitoring will be continued for one year after the end of the trial.

The principal outcome is the hearing loss defined by the difference between the average permanent threshold shift (PTS) in dB (decibel) at four pure tone high frequencies (9, 10, 12.5 and 14 kHz) using the data from the audiograms done before and after Cisplatin therapy, for each patient and for each ear. The average PTS in dB at these pure tone high frequencies will be compared between the treated and the control ears using a t-test for paired data. A planned interim analysis will be conducted when half of the anticipated participants would have completed the follow-up. In the interim analysis, the test for superiority will be done with two-sided alpha=0.01 and the results shown only to the Data and Safety Monitoring Committee (DSMC). If the DSMC recommendation is to continue the trial as planned, the final analysis will be done with two-sided alpha=0.045 in order to keep the trial overall statistical significance level to 0.05.

Exploratory analyses for secondary outcomes will assess 1) cochlear damage, specifically hair cell function obtained from the results of DPOAEs, ands 2) the difference between the PTS in dB at pure tone averages (0.5 to 8 kHz), which represent frequencies for speech perception. Other outcomes considered are ototoxicity severity according to CTCAE, and adverse effects of the transtympanic injections.

The investigators have established an independent DSMC to overview the conduct of the trial comprising experts in biostatistics, audiology, and haemato-oncology.

Efficacy of Trans-tympanic Injections of a Sodium Thiosulfate Gel to Prevent Cisplatin-induced Ototoxicity

Randomized Controlled Trial to Test the Efficacy of Trans-tympanic Injections of a Sodium Thiosulfate Gel to Prevent Cisplatin-induced Ototoxicity in Patients With Head and Neck Cancer

Hearing loss defined by the difference between the average permanent threshold shift (PTS) in dB (decibel) at four pure tone high frequencies (9, 10, 12.5 and 14 kHz) using the data from the audiograms done before and one month after Cisplatin therapy, for each patient and for each ear.

Cochlear damage defined by the difference between the distortion product otoacoustic emissions (DPOAEs) recording before and one month after Cisplatin therapy, for each patient and for each ear.

Hearing loss defined by the difference between the average permanent threshold shift (PTS) in dB (decibel) at four pure tone frequencies (0.5 to 8 kHz) using the data from the audiograms done before and one month and one year after Cisplatin therapy, for each patient and for each ear.

Ototoxicity severity according to CTCAE after each trans-tympanic injection

CHU de Quebec-Universite Laval

Researcher

Mouth and Tooth Diseases

Rare Diseases

Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

Pharyngeal Neoplasms

Otorhinolaryngologic Neoplasms

Nasopharyngeal Diseases

Pharyngeal Diseases

Stomatognathic Diseases

Drug: Endostar

Endostar 7.5mg / m2,3 cycles of intravenous infusion for ten days, and 2 cycles of maintenance therapy after radiotherapy

Drug: DDP

DDP 100mg / m2, intravenous infusion over 2 hours , for 2-3 cycles

Radiation: IMRT

IMRT:70-74Gy

Drug: DDP

DDP 100mg / m2, intravenous infusion over 2 hours , for 2-3 cycles

Radiation: IMRT

IMRT:70-74Gy

min kang, doctor

sheng ren wang, doctor

ming he lu, doctor

min shao lin, bachelor

zheng fu zhang, bachelor

yuan dai ma, doctor

A total of 300 patients with pathologically confirmed Locoregionally advanced nasopharyngeal carcinoma were enrolled. Patients were randomly divided into two groups, with 150 patients in each group. One group was treated with Concurrent Chemoradiotherapy combined with Endostar and the other group was treated with Concurrent Chemoradiotherapy. The short term efficacy and the toxic and side effects of these treatments were evaluated. The 1-year, 3-year, 5-year overall survival and progression-free survival of patients were analyzed. The investigators data may provide an alternative option for the treatment of Locoregionally advanced nasopharyngeal carcinoma with high efficacy and low toxicity.

This study was a multicenter, prospective, randomized controlled clinical trial. A set of unified standards were used, including the clinical research program, inclusion criteria, exclusion criteria, chemoradiotherapy regimen and evaluation criteria. Five medical centers participated in this study and 300 patients with pathologically confirmed Locoregionally advanced nasopharyngeal carcinoma were enrolled. These patients were stratified according to clinical stage and participating center, and were randomly divided into two groups: concurrent chemoradiotherapy combined with Endostar group ( IMRT 70-74Gy, Endostar 7.5mg / m2, 3 cycles of intravenous infusion, and 2 cycles of maintenance therapy after radiotherapy) and concurrent chemoradiotherapy group ( IMRT 70-74Gy, DDP 100mg / m2, intravenous infusion over 2 hours , for 2-3 cycles). After treatment, follow-up was performed every 3 months. The treatment toxicity, local control rate, distant metastasis-free survival, overall survival, progression-free survival were observed and assessed.

Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma

A Multicenter, Prospective, Randomized Controlled Clinical Trial Comparing Endostar With Concurrent Chemoradiotherapy and Concurrent Chemoradiotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)

The subjects were randomly divided into two groups. Group A: concurrent chemoradiotherapy combined with Endostar，including 3 cycles of intravenous infusion, and 2 cycles of maintenance therapy after radiotherapy，and Group B: concurrent chemoradiotherapy, concurrent chemotherapy for 2 or 3 cycles. After treatment, the subjects go into observation period. MRI will be used for evaluating the carcinoma status. During 3 years, any relapse or death will be recorded.

The subjects were randomly divided into two groups. Group A: concurrent chemoradiotherapy combined with Endostar，including 3 cycles of intravenous infusion, and 2 cycles of maintenance therapy after radiotherapy，and Group B: concurrent chemoradiotherapy, concurrent chemotherapy for 2 or 3 cycles. After treatment, the subjects go to observation period for 5 years.

First Affiliated Hospital of Guangxi Medical University

doctor

Digestive System Diseases

Carcinoma, Squamous Cell

Esophageal Squamous Cell Carcinoma

Neoplasms, Squamous Cell

Esophageal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Esophageal Diseases

Esophageal Cancer

Vinorelbine

Tubulin Modulators

Antimitotic Agents

Chang jian Hua, PD

Chang jian hua, PD

The aim of this study is to explore whether endostar combined with NVB and DDP as treatment could improve progression-free surial time (PFS) and to evaluate the safety of the chemotherapy regimens

This study is to explore whether endostar combined with NVB and DDP as treatment could improve progression-free surial time (PFS) and to evaluate the safety of the chemotherapy regimens used as second-line treatment of advanced esophageal squamous cell carcinomas

Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas of the Prospective, Single Arm Phase II Clinical Study

Fudan University

Chief Physician

Skin and Connective Tissue Diseases

Immune System Diseases

Breast Neoplasms

Triple Negative Breast Neoplasms

Hypersensitivity

Breast Diseases

Skin Diseases

Vinorelbine:25 mg/m2, D1, D8 every 21 days

DDP:75 mg/m2, D1 every 21 days

Vinorelbine:30 mg/m2, D1, D8 every 21 days

Xichun Hu, MD, PhD

Zhonghua Wang, MD

Xichun Hu, MD,PhD

Platinum Retreated in Patients with Platinum Sensitive mTNBC

Platinum Retreated in Second- or Third-line Patients with Platinum Sensitive Metastatic Triple Negative Breast Cancer (randomised, phase II, NPN trial)

Platinum Rechallenge in Patients With Platinum-sensitive mTNBC

Platinum Retreated in Second- or Third-line Patients With Platinum Sensitive Metastatic Triple Negative Breast Cancer (Randomised, Phase II, NPN Trial)

Vice Director of department of medical oncology

Irinotecan

Topoisomerase I Inhibitors

Enzyme Inhibitors

Endostar15mg/m2 Irinotecan 60mg/m2，D1，8 DDP 60mg/m2，D1

chang jian hua, PD

wang hui jie, doctor

The aim of this study is to explore whether endostar combined with IP as treatment could improve progression-free surial time (PFS) and to evaluate the safety of the chemotherapy regimens

This study is to explore whether endostar combined with IP as treatment could improve progression-free surial time (PFS) and to evaluate the safety of the chemotherapy regimens used as second-line treatment of advanced esophageal squamous cell carcinomas

Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas of the Prospective, Single Arm Phase II Clinical Study

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Uterine Cervical Neoplasms

Uterine Neoplasms

Genital Neoplasms, Female

Urogenital Neoplasms

Uterine Cervical Diseases

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Bevacizumab

Docetaxel

Antineoplastic Agents, Immunological

bevacizumab combined with neoadjuvant chemotherapy and concurrent chemoradiotherapy：

1. bevacizumab combined with neoadjuvant chemotherapy for 2 cycles: Bevacizumab will be used as 7.5 mg/kg, once every three weeks; DDP 75mg/m2, intravenous injection，once three week; Docetaxel 75mg/m2, intravenous injection，once three week;
2. bevacizumab combined with concurrent chemoradiotherapy: Bevacizumab will be used as 7.5 mg/kg, once every three weeks; DDP 75mg/m2, intravenous injection，once three week pelvic radiotherapy will be delivered with 45-50Gy/25f; enlarged lymph nodes be irradiated by 62.5Gy/25f with sib-IMRT; brachytherapy be delivered to cervix and primary tumor

study arm: bevacizumab combined with concurrent chemoradiotherapy： Bevacizumab will be used as 7.5 mg/kg, once every three weeks; DDP 75mg/m2, intravenous injection，once three week; pelvic radiotherapy will be delivered with 45-50Gy/25f; enlarged lymph nodes be irradiated by 62.5Gy/25f with sib-IMRT; brachytherapy be delivered to cervix and primary tumor

standard concurrent chemoradiotherapy: DDP 40mg/m2, intravenous injection，once a week; pelvic radiotherapy will be delivered with 45-50Gy/25f; enlarged lymph nodes be irradiated by 62.5Gy/25f with sib-IMRT; brachytherapy be delivered to cervix and primary tumor

bevacizumab will be used during neoadjuvant and concurrent chemoradiotherapy

bevacizumab

DDP will be used during neoadjuvant and concurrent chemoradiotherapy

standard treatment includes pelvic external beam radiation and brachytherapy

radiotherapy

Lichun Wei, physician

ying zhang, physician

Lichun Wei, MD

Li-Chun Wei, M.D.,Ph.D

ying zhang, M.D.,Ph.D

hua yang, M.D.

jianping Li, M.D.,Ph.D

weiwei Li, M.D.

Lina Zhao, M.D.,Ph.D

Mei Shi, M.D.,Ph.D

mei shi, M.D.

To verify the clinical efficacy and safety of bevacizumab in treating local advanced cervical cancer, present study was designed to investigate the clinical results of bevacizumab combined with concurrent chemoradiotherapy (CCRT) in local advanced cervical cancer

Cervical cancer is the most common malignant tumor of the female productive system in developing countries and regions. Since five large-sample randomized controlled clinical trials have reported that concurrent chemoradiotherapy can improve the survival rate of patients with cervical cancer in the early 20th century, cisplatin-based concurrent chemoradiotherapy has become the standard treatment for locally advanced cervical cancer (LACC) . LACC has the characteristics of high invasiveness, high lymphatic metastasis and poor prognosis. The size and stage of the tumor are two independent prognostic factors. In 2008, a retrospective study published in Journal of Clinical Oncology(JCO) suggested that single-agent concurrent chemoradiotherapy did not improve disease-free survival (DFS) or overall survival (OS) for patients with FIGO stage II-IVA tumors. Multiple studies reported poor prognosis in patients with primary tumors whose diameters were larger than 4 cm, 5 cm or 6 cm , and in 2016, Fokdal. et al. reported a low local control rate if the residual tumor volume was larger than 30 cc prior to afterloading brachytherapy . In the EMBRACE trial, Jastaniyah et al. divided tumors into five groups based on the difference between the tumor volume before treatment and prior to afterloading brachytherapy, and found that the dose coverage of the HR-CTV by D90 was low for patients with a large primary tumor volume and a poor treatment response \[13\]. Therefore, for patients with a large primary tumor volume, further studies are required to investigate whether accelerated tumor volume regression prior to afterloading brachytherapy is meaningful to escalating the local afterloading dose delivered to tumor and improving the local control rate and OS.

In recent years, with the rapid development of molecular biology, there have been multiple clinical trials regarding the molecular targeted drug therapy for tumor cell-specific targets . The angiogenesis inhibitor, bevacizumab, is the first molecular targeted drug for recurrent or advanced cervical cancer, which inhibits tumor angiogenesis by blocking the function of the vascular endothelial growth factor (VEGF). In a GOG phase II clinical trial, bevacizumab was applied to 46 patients with recurrent cervical cancer. The study reported a progression-free survival (PFS) of more than 6 months, with a median PFS and a median OS of 3.50 months and 7.29 months, respectively. Another GOG240 phase III clinical trial showed that chemotherapy combined with bevacizumab extended the OS of patients with recurrent and metastatic cervical cancer. United States' NCCN Clinical Practice Guidelines recommend the combined use of bevacizumab with paclitaxel + cisplatin for the first-line treatment of current and metastatic cervical cancer. However, there is a lack of evidence for the use of bevacizumab in the treatment of LACC.

The above background information raises the questions of: during the initial treatment of LACC, can the introduction of bevacizumab improve the patient's tumor regression rate and OS? And compared to concurrent chemoradiotherapy directly combined with bevacizumab, can neoadjuvant chemotherapy combined with bevacizumab + concurrent chemoradiotherapy further improve the therapeutic outcome? However, currently there is no research on these topics. In 2017, our research team reported poor prognosis in patients with LACC who had a high VEGFR expression . This result indicated that anti-angiogenic therapy could benefit patients with LACC. To investigate the clinical efficacy and safety of bevacizumab in treating local advanced cervical cancer, we design this clinical study

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma	NCT03086681	Cervical Carcin...	Endostar DDP	18 Years - 65 Years	First Affiliated Hospital of Guangxi Medical University
Efficacy of Trans-tympanic Injections of a Sodium Thiosulfate Gel to Prevent Cisplatin-induced Ototoxicity	NCT02281006	DDP Head and Neck C... Adverse Effect	Trans-tympanic ...	18 Years -	CHU de Quebec-Universite Laval
Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma	NCT02907710	Nasopharyngeal ...	Endostar DDP	18 Years - 70 Years	First Affiliated Hospital of Guangxi Medical University
Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma	NCT03086681	Cervical Carcin...	Endostar DDP	18 Years - 65 Years	First Affiliated Hospital of Guangxi Medical University
Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas	NCT02665702	Esophageal Squa...	NVB DDP Endostar	18 Years - 75 Years	Fudan University
Platinum Rechallenge in Patients With Platinum-sensitive mTNBC	NCT02607215	Metastatic Brea...	Vinorelbine DDP	18 Years - 70 Years	Fudan University
Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas	NCT03797625	Esophageal Squa...	Irinotecan DDP Endostar	18 Years - 75 Years	Fudan University
A Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical Cancer	NCT04138992	Disease Free Su...	bevacizumab DDP Docetaxel radiotherapy	18 Years - 65 Years	Air Force Military Medical University, China
Efficacy of Trans-tympanic Injections of a Sodium Thiosulfate Gel to Prevent Cisplatin-induced Ototoxicity	NCT02281006	DDP Head and Neck C... Adverse Effect	Trans-tympanic ...	18 Years -	CHU de Quebec-Universite Laval
A Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical Cancer	NCT04138992	Disease Free Su...	bevacizumab DDP Docetaxel radiotherapy	18 Years - 65 Years	Air Force Military Medical University, China
Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma	NCT03086681	Cervical Carcin...	Endostar DDP	18 Years - 65 Years	First Affiliated Hospital of Guangxi Medical University

Spots Global Cancer Trial Database for ddp

Every month we try and update this database with for ddp cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for ddp

Every month we try and update this database with for ddp cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for ddp cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.